Preventive Medicine Reports
August 1, 2025
Pedro J. Teixeira, Rakesh Jain, Andrew Penn et al.
1 citation
Psychedelics have been increasingly studied for their potential to influence mental health and well-being, yet their relationship with broader health behaviors remains underexplored. This study examined associations between lifetime psychedelic use and health-related behaviors, including substance use, dietary habits, and impulsive tendencies. Using an extensive cross-sectional online survey,...
CNS Drugs
November 1, 2024
Roger S McIntyre, Rakesh Jain
58 citations
Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates. In the past 2 decades, a promising target emerged to improve patient outcomes in depression treatment:...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2023
Zachary Herrmann, Adam W. Levin, Steven P Cole et al.
9 citations
Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a...
Frontiers in Psychiatry
2022
Charles L. Raison, Rakesh Jain, Andrew Penn et al.
75 citations
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A...